Hyalex Orthopaedics announced today that patients successfully received knee implants as part of its first-in-human clinical trials.
The procedures came as part of two prospective, studies for the Hyalex Knee Cartilage System in the U.S. and Europe. Sites for both studies already enrolled and treated patients with the synthetic cartilage technology. The technology has FDA investigational device exemption as well.
Lexington, Massachusetts-based Hyalex designed the cartilage to replicate the structure and function of hyaline cartilage of the joints. It incorporates components that provide both strength and lubrication to replace painful cartilage lesions and immediately restore the knee surface. The technology matches the strong and slippery properties of the body’s native cartilage.
The company said its unique design allows surgeons to treat patients with or without bony involvement. Following implantation in the trials, investigators will regularly…